A controversial discussion on the occurrence of the RNA modification m 1 A in mRNA takes a new turn, as an antibody with a central role in modification mapping was shown to also bind mRNA cap structures.
Off-target binding of antibodies is a widespread problem More recently, studies in the DNA modification field have begun to identify sources of artifacts. For example, issues of inherent cross-reactivity can be amplified by low abundance of the primary epitope. This is exemplified by the cross-reactivity of antibodies to contaminating bacterial nucleic acids that can confound the modification analysis of eukaryotic DNA 8 . Of note, the existence of dm 6 A and dm 4 C in DNA of higher eukaryotes 9, 10 has been questioned by an antibody-independent analysis 11 . Another recent study has shown that several antibodies directed toward DNA modification cross-react with short tandem repeats in a modification-independent manner, which can in turn generate experimental noise as high as 99% 12 .
Given that the development of such antibodies includes a conjugation step to a protein via the oxidized sugar moiety of a modified nucleoside 13 , modification-specific antibodies could be expected to recognize the modified nucleobase irrespective of whether they are found in DNA or RNA. Thus, the demonstration of specificity problems in MeRIP experiments in the current publication by Grozhik et al. should not come as a surprise; rather it is a long awaited, experimentally thorough and convincing demonstration of antibody-dependent artifacts in the RNA modification field 1 . In addition to providing experimental guidelines for the field as a whole, the study also uncovers the unexpected binding of a commercially available anti-m 1 A antibody to cap structures. Furthermore, the study provides important clarifications in the controversial discussion regarding the number of m 1 A residues present in mammalian mRNA, which have been reported in several publications [14] [15] [16] [17] . More specifically, the results reported by Grozhik et al. suggest that m 1 A is infrequent in mRNA, and that the prevalence of this modification was substantially overestimated in previous studies. A comparative assessment of two m 1 A antibodies led to vastly different results in MeRIP-type experiments, likely pointing to a general problem in the field. For one, specifications and specificity claims for a given antibody should be taken with caution and preferably confirmed for each application using the relevant controls. Secondly, it should now be clear that confirming antibody specificity by simple methods such as dot blot experiments should be considered insufficient 18 . Of the many validation techniques that the field has developed 6 , Grozhik et al. judiciously applied mass spectrometry and thin layer chromatography to characterize the physicochemical properties of material isolated by MeRIP 1 . A systematic characterization of the various antibodies commonly used might be highly beneficial, as was shown in the not-so-distant field of histone modifications. There, a systematic evaluation of antibody specificity was conducted using peptide-arrays, and revealed substantial specificity problems already several years ago 19 .
Considerations beyond antibody specificity
On a more fundamental level, one might question if a single methyl group in a nucleic acid fragment can really provide a sufficient level of selectivity for MeRIP or other similar techniques. Although our understanding of binding modes is limited, it is clear that the primary epitope can not only be the modification itself (i.e. a methyl group), but can extend to the modified nucleobase (i.e. adenine) and beyond. It follows that all adenines present in the RNA also compete for binding, albeit with lower affinity than the methylated adenine. In such a situation, the enrichment will be governed by the relative affinities toward modified and unmodified residues, and by their relative abundances. This, in turn, means, that any adenine in unmodified RNA (including polyA-tails) may give rise to non-specific binding, especially if the modification is of low abundance. It is thus perhaps not surprising that enrichment factors reported in MeRIP experiments are as low as 4-10-fold 20 . For relatively abundant modifications, such as m 6 A, this may still be sufficient to produce credible mapping results. However, this may not be the case for less abundant RNA modifications.
With respect to MeRIP in general, several additional problems exist that extend beyond antibody specificity, and which could skew the results of modification mapping experiments. A number of these problems are related to the experimental design of Illumina sequencing and library preparation protocols used. For example, early modification calling reports have neglected the use of unique molecular identifiers (UMI) 6 , leading to artificial amplification of noise by PCR 21 . Potential artifacts resulting from RNA-Seq adapter design have also been discussed 22 . Moreover, problems in the computational analysis of RNA-Seq data, such as ambiguity in read mapping, are among the known error sources 23 . Finally, the field needs standards for stringent statistical data analysis 24 . Taking into account all these limitations, the massive datasets obtained by newly reported mapping techniques for RNA modification analysis should be considered collections of candidate modification sites, rather than experimentally confirmed modification landscapes. Therefore, further efforts should aim to develop and apply multiple orthogonal methods for the validation of modification sites and genome-wide patterns 6 .
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